U.S. Online Retail and Ecommerce Stock News

NasdaqCM:CELC
NasdaqCM:CELCBiotechs

Is It Too Late To Consider Celcuity (CELC) After Its Recent Share Price Surge?

If you are wondering whether Celcuity at US$139.44 still offers value after its run, the key question is how its fundamentals stack up against that price. The stock has moved sharply in recent periods, with returns of 17.2% over 7 days, 22.1% over 30 days, 38.7% year to date, and a very large 1 year gain accompanied by a 3 year return of 13x and a 5 year return of 4x. These moves sit against a backdrop of ongoing interest in Celcuity's role in the pharmaceuticals and biotech space. In this...
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives

Exelixis (EXEL) opened 2026 with Q1 revenue of US$610.8 million and basic EPS of US$0.81, setting a clear marker for how the year is starting to shape up. The company has seen quarterly revenue move from US$555.4 million in Q1 2025 to US$610.8 million in Q1 2026, while basic EPS over that same span shifted from US$0.57 to US$0.81. This is prompting investors to focus on how sustained profitability and margins might influence sentiment around the latest numbers. See our full analysis for...
NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

US Stock Market Today S&P 500 Futures Edge Higher As Rate Relief Hopes Build

The Morning Bull - US Market Morning Update Thursday, May, 7 2026 E-mini S&P 500 futures are a touch higher this morning, as investors weigh easing tensions in the Middle East against fresh signs of a mixed global economy. Hopes for progress in US Iran talks have pushed oil prices lower and pulled the US 10 year Treasury yield down to around 4.35%, which can ease borrowing costs for households and companies. At the same time, US private employers added 109,000 jobs in April, the strongest...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors

Protagonist Therapeutics (PTGX) opened 2026 with Q1 revenue of US$56.4 million, Basic EPS of US$0.06 and net income of US$3.8 million, while trailing 12 month figures show revenue of US$74.1 million, a Basic EPS loss of US$1.79 and a net loss of US$114.7 million. Over the past year, the company has seen quarterly revenue move between US$4.7 million and US$170.6 million, alongside Basic EPS that has ranged from a US$2.11 profit to a US$0.69 loss. These figures give investors a broad set of...
NasdaqGS:LECO
NasdaqGS:LECOMachinery

Why Lincoln Electric (LECO) Is Up 6.7% After Strong Q1 Earnings And Brand Recognition Boost

Lincoln Electric Holdings reported first-quarter 2026 results with sales rising to US$1,121.43 million and net income reaching US$136.38 million, alongside higher basic and diluted earnings per share from continuing operations compared with a year earlier. Following these results, the company’s inclusion in Newsweek’s 2026 list of America’s Most Patriotic Companies and its CFO’s recent appearance at Oppenheimer’s Industrial Growth Conference highlight a blend of financial progress and brand...
NasdaqGM:TTD
NasdaqGM:TTDMedia

Trade Desk Faces UID2 Oversight Questions After CTV Implementation Errors

A major connected TV publisher made technical errors implementing The Trade Desk's Unified ID 2.0 protocol. The Trade Desk, which oversees UID2 and operates a demand side platform, did not catch the issues during oversight. The incident has triggered industry criticism around accountability, data quality controls and governance for UID2. Questions are emerging about advertiser trust and the broader adoption of UID2 across the digital ad ecosystem. The Trade Desk (NasdaqGM:TTD) sits at the...
NasdaqGS:POWL
NasdaqGS:POWLElectrical

Is It Too Late To Consider Powell Industries (POWL) After Its Surging Share Price?

If you are wondering whether Powell Industries at around US$320 per share still offers value, it helps to separate headline returns from what the underlying valuation is actually saying. The stock has posted very strong returns, with gains of 26.4% over the last week, 71.5% over the past month, 172.6% year to date and 451.6% over the last year, plus a multi year return of more than 17x. Recent coverage has focused on Powell Industries as part of broader discussions around power...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

Evaluating First Bancorp (FBNC) After Earnings Beat Fuels Investor Optimism

First Bancorp (FBNC) is back on investors’ radar after its latest quarterly report, where revenue and net interest income exceeded analyst expectations and recent board appointments added fresh perspectives to the regional bank’s story. See our latest analysis for First Bancorp. The stock has been firming up, with a 1-day share price return of 2.11% and a year to date share price return of 16.07%. The 1-year total shareholder return of 45.49% and 3-year total shareholder return of 130.20%...
NasdaqGS:CIFR
NasdaqGS:CIFRSoftware

Cipher Digital Leans Into AI Data Centers As Bitcoin Exit Accelerates

Cipher Digital (NasdaqGS:CIFR) signed its third long term AI and high performance computing data center campus lease with an investment grade hyperscale tenant. The company completed a $2b high yield bond offering and closed a $200m revolving credit facility to fund its Black Pearl project and support further expansion. Cipher Digital has started winding down its Bitcoin mining operations, targeting a full exit and asset repurposing for HPC opportunities by the end of 2027. Cipher Digital...
NasdaqGS:VECO
NasdaqGS:VECOSemiconductor

Veeco Instruments (VECO) Margin Compression And Q1 Loss Test Bullish Growth Narratives

Veeco Instruments (VECO) opened 2026 with Q1 revenue of US$158.3 million, basic EPS of roughly a US$0.01 loss, and trailing 12‑month EPS of US$0.39 on US$655.3 million of revenue, setting up a quarter where profitability was in focus. The company has seen quarterly revenue move from US$167.3 million and basic EPS of US$0.21 in Q1 2025 to US$158.3 million and a small loss in Q1 2026, while trailing 12‑month EPS moved from US$1.31 on US$717.3 million of revenue at Q4 2024 to US$0.39 on US$655.3...
NYSE:AIR
NYSE:AIRAerospace & Defense

Has AAR (AIR) Risen Too Far After Recent Aerospace And Defense Sector Interest

If you are wondering whether AAR at US$118.71 is still reasonably priced after a strong run, this article walks through what the current share price might imply about value. The stock has recent returns of 12.3% over 7 days, 4.1% over 30 days, 40.6% year to date and 101.0% over the last year, which naturally raises questions about how much upside or risk is now priced in. Recent headlines have focused on AAR's role within the broader Aerospace & Defense sector and how investors are reacting...
NasdaqGM:ADMA
NasdaqGM:ADMABiotechs

ASCENIV Pediatric Approval Tests ADMA Biologics Growth Story And Risks

FDA approves an expanded label for ASCENIV to include pediatric immunodeficiency patients aged two and older. The decision allows earlier intervention for immune compromised children and broadens ASCENIV’s eligible patient pool. The approval fulfills a key post marketing commitment for ADMA Biologics and may influence future commercial uptake. For ADMA Biologics (NasdaqGM:ADMA), this regulatory milestone arrives with the stock trading at $10.08 after a very large 5 year return and a 182.4%...
NasdaqCM:AHG
NasdaqCM:AHGHealthcare

Is Akso Health Group's (AHG) Early BCI Bet Quietly Redefining Its Long-Term Innovation Narrative?

In April 2026, Akso Health Group announced it had begun a next-generation Brain-Computer Interface research and development program, building foundational infrastructure to pursue ultra-high-resolution neural sensing, real-time AI neural decoding, and advanced interface design, with related patent applications pending. The company emphasized that it has not yet started human clinical trials, made any regulatory submissions, or generated revenue from BCI activities, underscoring the...
NYSE:ONTO
NYSE:ONTOSemiconductor

Onto Innovation (ONTO) Margin Reset From 21.3% To 10.3% Tests Bullish Growth Narratives

Onto Innovation (ONTO) has opened 2026 with Q1 revenue of US$291.9 million and basic EPS of US$0.68, setting a clear benchmark for how the rest of the year may shape up. The company has seen quarterly revenue move between US$218.2 million and US$291.9 million over the last six reported periods, while basic EPS has ranged from US$0.21 to US$1.30. This gives investors a concrete sense of how top line and per share earnings have tracked through recent cycles. With trailing 12 month net profit...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

Perrigo (PRGO) Q1 Loss Of US$389.9 Million Tests Profit-Recovery Narratives

Perrigo (PRGO) opened Q1 2026 with revenue of US$969.2 million and a basic EPS loss of US$2.81, while net income excluding extra items came in at a loss of US$389.9 million. Over the past six reported quarters, revenue has ranged between US$969.2 million and US$1.14 billion and basic EPS has moved from a small profit of US$0.09 in Q3 2025 to a loss of US$10.20 in Q4 2025 and US$2.81 in the latest quarter, giving investors a wide view of how the income statement has changed across different...